{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:02:17Z","timestamp":1789621337548,"version":"build-2803163510"},"reference-count":281,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health (USA) NCI","doi-asserted-by":"publisher","award":["5R01CA262145"],"award-info":[{"award-number":["5R01CA262145"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"ARTNet","doi-asserted-by":"publisher","award":["5U54CA224019"],"award-info":[{"award-number":["5U54CA224019"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"OHSU"},{"id":[{"id":"https:\/\/ror.org\/009avj582","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Despite significant advances in treatment for several hematologic malignancies, treatment resistance and relapse remain major challenges. Immune escape is recognized as a key mechanism that can lead to tumor evasion and treatment resistance in blood cancers. Among the various drivers of immune evasion, epigenetic dysregulation is a recurrent and central feature in these malignancies. Although epigenetic targeting therapies have shown benefit in blood cancers, relapse still occurs, indicating the need for improved therapies. This review focuses on epigenetic mechanisms causing immune evasion in blood cancers and discusses emerging therapies that focus on combining epigenetic modulators with immunotherapies to improve anti-tumor immunity. We focus on how epigenetic mechanisms, including DNA methylation, histone modification and chromatin remodeling, influence tumor cells or immune cell subsets including T cells, NK cells and macrophages to promote tumor growth. We then discuss immunomodulatory effects of epigenetic therapies including DNA methyltransferase inhibitors and histone deacetylase inhibitors and how they can restore immune cell function and limit tumor growth and progression. Finally, we highlight the potential of combining epigenetics with different immunotherapies including adoptive cell therapy and immune checkpoint blockade, while discussing their current limitations and suggesting ways to overcome this therapy resistance. A deeper understanding of the immune\u2013epigenetic axis in blood cancers may facilitate the development of effective therapies that will benefit patients with hematologic malignancies.<\/jats:p>","DOI":"10.3390\/cancers18182985","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:33:42Z","timestamp":1789479222000},"page":"2985","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting the Epigenetic\u2013Immune Axes in Hematologic Malignancies"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6110-6608","authenticated-orcid":false,"given":"Ravina","family":"Pandita","sequence":"first","affiliation":[{"name":"Graduate Program in Biomedical Sciences, Oregon Health & Science University, Portland, OR 97239 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan F.","family":"Lind","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, OR 97239, USA"},{"name":"Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA"},{"name":"Department of Cell, Development and Cancer Biology, Oregon Health & Science University, Portland, OR 97239, USA"},{"name":"Department of Pediatrics, Oregon Health & Science University, Portland, OR 97239, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"ref_1","unstructured":"(2026, July 27). Blood Cancer Facts and Statistics | Blood Cancer United. Available online: https:\/\/bloodcancerunited.org\/blood-cancer\/blood-cancer-facts-and-statistics."},{"key":"ref_2","unstructured":"(2026, April 30). Acute Myeloid Leukemia\u2014Cancer Stat Facts, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Thandra, K.C., Barsouk, A., Saginala, K., Padala, S.A., Barsouk, A., and Rawla, P. (2021). Epidemiology of Non-Hodgkin\u2019s Lymphoma. Med. Sci., 9.","DOI":"10.3390\/medsci9010005"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering (Asymptomatic) Multiple Myeloma: IMWG Consensus Perspectives Risk Factors for Progression and Guidelines for Monitoring and Management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.18632\/oncotarget.1497","article-title":"Drug Resistance in Multiple Myeloma: Latest Findings and New Concepts on Molecular Mechanisms","volume":"4","author":"Abdi","year":"2013","journal-title":"Oncotarget"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and Management of Multiple Myeloma: A Review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.3324\/haematol.2021.279360","article-title":"Comprehensive Genomic Analysis of Refractory Multiple Myeloma Reveals a Complex Mutational Landscape Associated with Drug Resistance and Novel Therapeutic Vulnerabilities","volume":"107","author":"Giesen","year":"2022","journal-title":"Haematologica"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1038\/s41467-022-31430-0","article-title":"The Genetic Heterogeneity and Drug Resistance Mechanisms of Relapsed Refractory Multiple Myeloma","volume":"13","author":"Vo","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.3324\/haematol.2017.184192","article-title":"Hide or Defend, the Two Strategies of Lymphoma Immune Evasion: Potential Implications for Immunotherapy","volume":"103","author":"Houot","year":"2018","journal-title":"Haematologica"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"103164","DOI":"10.1016\/j.critrevonc.2020.103164","article-title":"Immune Evasion Mechanisms in Acute Myeloid Leukemia: A Focus on Immune Checkpoint Pathways","volume":"157","author":"Taghiloo","year":"2021","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1158\/1078-0432.CCR-15-2626","article-title":"T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients","volume":"22","author":"Kong","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e120974","DOI":"10.1172\/jci.insight.120974","article-title":"Signatures of CD8+ T Cell Dysfunction in AML Patients and Their Reversibility with Response to Chemotherapy","volume":"3","author":"Knaus","year":"2018","journal-title":"JCI Insight"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"14331","DOI":"10.1073\/pnas.1916206117","article-title":"Reversible Suppression of T Cell Function in the Bone Marrow Microenvironment of Acute Myeloid Leukemia","volume":"117","author":"Lamble","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1158\/1078-0432.CCR-08-3010","article-title":"Increased Frequency and Suppression by Regulatory T Cells in Patients with Acute Myelogenous Leukemia","volume":"15","author":"Szczepanski","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Wang, M., Zhang, C., Tian, T., Zhang, T., Wang, R., Han, F., Zhong, C., Hua, M., and Ma, D. (2018). Increased Regulatory T Cells in Peripheral Blood of Acute Myeloid Leukemia Patients Rely on Tumor Necrosis Factor (TNF)-\u03b1\u2013TNF Receptor-2 Pathway. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01274"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1182\/blood-2011-07-365817","article-title":"Regulatory T Cells in Acute Myelogenous Leukemia: Is It Time for Immunomodulation?","volume":"118","author":"Ustun","year":"2011","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Rovatti, P.E., Gambacorta, V., Lorentino, F., Ciceri, F., and Vago, L. (2020). Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00147"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41375-021-01350-x","article-title":"Catch Me If You Can: How AML and Its Niche Escape Immunotherapy","volume":"36","author":"Tettamanti","year":"2022","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.20.00475","article-title":"Immune Biology of Acute Myeloid Leukemia: Implications for Immunotherapy","volume":"39","author":"Khaldoyanidi","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/ajcp\/aqab154","article-title":"Immune Escape Mechanisms in Intravascular Large B-Cell Lymphoma: A Molecular Cytogenetic and Immunohistochemical Study","volume":"157","author":"Patel","year":"2022","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Menter, T., and Tzankov, A. (2018). Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00054"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1038\/s41375-020-0737-9","article-title":"PD-L1\/L2 Protein Levels Rapidly Increase on Monocytes via Trogocytosis from Tumor Cells in Classical Hodgkin Lymphoma","volume":"34","author":"Kawashima","year":"2020","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-022-01234-2","article-title":"Deciphering Mechanisms of Immune Escape to Inform Immunotherapeutic Strategies in Multiple Myeloma","volume":"15","author":"Swamydas","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Wang, C., Wang, W., Wang, M., Deng, J., Sun, C., Hu, Y., and Luo, S. (2024). Different Evasion Strategies in Multiple Myeloma. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1346211"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Botta, C., Mendicino, F., Martino, E.A., Vigna, E., Ronchetti, D., Correale, P., Morabito, F., Neri, A., and Gentile, M. (2021). Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities. Cancers, 13.","DOI":"10.3390\/cancers13133213"},{"key":"ref_28","unstructured":"van Putten, L.M., Balner, H., Muller-B\u00e9rat, C.N., de Vries, M.J., and Van Bekkum, D.W. (1968). Progress in the Treatment and Prevention of Secondary Disease after Homologous Bone Marrow Transplantation in Monkeys: Effects of Chemotherapy and of Donor Selection by Histocompatibility Testing. Current Studies in Hematology and Blood Transfusion, Karger Publishers."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Dickinson, A.M., Norden, J., Li, S., Hromadnikova, I., Schmid, C., Schmetzer, H., and Jochem-Kolb, H. (2017). Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.00496"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1056\/NEJM197905103001902","article-title":"Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts","volume":"300","author":"Weiden","year":"1979","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor Leukocyte Transfusions for Treatment of Recurrent Chronic Myelogenous Leukemia in Marrow Transplant Patients","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients with Relapsed Low-Grade Non-Hodgkin\u2019s Lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00432-021-03833-x","article-title":"Anti-CD19 Monoclonal Antibodies for the Treatment of Relapsed or Refractory B-Cell Malignancies: A Narrative Review with Focus on Diffuse Large B-Cell Lymphoma","volume":"148","author":"Zinzani","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/14712598.2020.1822318","article-title":"Anti-CD20 Treatment for B-Cell Malignancies: Current Status and Future Directions","volume":"21","author":"Klein","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1634\/theoncologist.2018-0179","article-title":"FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia","volume":"23","author":"Pulte","year":"2018","journal-title":"Oncologist"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/2643-3230.BCD-23-0176","article-title":"An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple Myeloma","volume":"4","author":"Firestone","year":"2023","journal-title":"Blood Cancer Discov."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.trecan.2024.06.001","article-title":"Current Landscape of CD3 Bispecific Antibodies in Hematologic Malignancies","volume":"10","author":"Kassner","year":"2024","journal-title":"Trends Cancer"},{"key":"ref_38","first-page":"e11504","article-title":"Yescarta: A New Era for Non-Hodgkin Lymphoma Patients","volume":"12","author":"AlDallal","year":"2020","journal-title":"Cureus"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2210046","DOI":"10.1080\/21645515.2023.2210046","article-title":"Kymriah\u00ae (Tisagenlecleucel)\u2014An Overview of the Clinical Development Journey of the First Approved CAR-T Therapy","volume":"19","author":"Awasthi","year":"2023","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T Therapies in Multiple Myeloma: Unleashing the Future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e120505","DOI":"10.1172\/jci.insight.120505","article-title":"Anti-CD19 CAR T Cells with High-Dose Melphalan and Autologous Stem Cell Transplantation for Refractory Multiple Myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"JCI Insight"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/gt.2012.48","article-title":"Effector Memory and Central Memory NY-ESO-1-Specific Re-Directed T Cells for Treatment of Multiple Myeloma","volume":"20","author":"Schuberth","year":"2013","journal-title":"Gene Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin\u2019s Lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Jin, S., Zhang, Y., Zhou, F., Chen, X., Sheng, J., and Zhang, J. (2022). TIGIT: A Promising Target to Overcome the Barrier of Immunotherapy in Hematological Malignancies. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1091782"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-020-00947-6","article-title":"Targeting Immune Checkpoints in Hematological Malignancies","volume":"13","author":"Salik","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41392-023-01342-6","article-title":"Epigenetic Regulation in Hematopoiesis and Its Implications in the Targeted Therapy of Hematologic Malignancies","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1182\/blood-2011-02-339747","article-title":"TET2 Mutation Is an Unfavorable Prognostic Factor in Acute Myeloid Leukemia Patients with Intermediate-Risk Cytogenetics","volume":"118","author":"Chou","year":"2011","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41408-025-01287-9","article-title":"Genomic and Transcriptomic Determinants of Clinical Outcomes in Patients with AML and DNMT3A Mutations","volume":"15","author":"Ni","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.1182\/bloodadvances.2022008282","article-title":"Characteristics and Prognostic Impact of IDH Mutations in AML: A COG, SWOG, and ECOG Analysis","volume":"7","author":"Alonzo","year":"2023","journal-title":"Blood Adv."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"110626","DOI":"10.1016\/j.cellsig.2023.110626","article-title":"DNMT3A R882H Mutation Promotes Acute Leukemic Cell Survival by Regulating Glycolysis through the NRF2\/NQO1 Axis","volume":"105","author":"Chu","year":"2023","journal-title":"Cell. Signal."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1158\/0008-5472.CAN-20-3033","article-title":"Alterations to DNMT3A in Hematologic Malignancies","volume":"81","author":"Venugopal","year":"2021","journal-title":"Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1186\/s12967-023-04323-z","article-title":"DNMT3A Mutation Promotes Leukemia Development through NAM-NAD Metabolic Reprogramming","volume":"21","author":"Yang","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/npp.2012.112","article-title":"DNA Methylation and Its Basic Function","volume":"38","author":"Moore","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1038\/s41467-019-12159-9","article-title":"DNA Methylation Loss Promotes Immune Evasion of Tumours with High Mutation and Copy Number Load","volume":"10","author":"Jung","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood-2018-02-692970","article-title":"Insight into Origins, Mechanisms, and Utility of DNA Methylation in B-Cell Malignancies","volume":"132","author":"Oakes","year":"2018","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"7414","DOI":"10.1073\/pnas.1703577114","article-title":"DNA Methylation Markers for Diagnosis and Prognosis of Common Cancers","volume":"114","author":"Hao","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1038\/sj.onc.1208540","article-title":"De Novo DNA Methyltransferases Dnmt3a and Dnmt3b Primarily Mediate the Cytotoxic Effect of 5-Aza-2\u2032-Deoxycytidine","volume":"24","author":"Oka","year":"2005","journal-title":"Oncogene"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/5047","article-title":"Synergy of Demethylation and Histone Deacetylase Inhibition in the Re-Expression of Genes Silenced in Cancer","volume":"21","author":"Cameron","year":"1999","journal-title":"Nat. Genet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/416552a","article-title":"DNMT1 and DNMT3b Cooperate to Silence Genes in Human Cancer Cells","volume":"416","author":"Rhee","year":"2002","journal-title":"Nature"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.1128\/MCB.19.10.6690","article-title":"Roles of Cell Division and Gene Transcription in the Methylation of CpG Islands","volume":"19","author":"Bender","year":"1999","journal-title":"Mol. Cell. Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_62","first-page":"807","article-title":"Decitabine in the Treatment of Myelodysplastic Syndromes","volume":"3","author":"Saba","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/leu.2017.186","article-title":"A Phase II, Multicentre Trial of Decitabine in Higher-Risk Chronic Myelomonocytic Leukemia","volume":"32","author":"Santini","year":"2018","journal-title":"Leukemia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1056\/NEJMoa2510223","article-title":"All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia","volume":"394","author":"Roboz","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/cr.2011.22","article-title":"Regulation of Chromatin by Histone Modifications","volume":"21","author":"Bannister","year":"2011","journal-title":"Cell Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/j.molcel.2023.04.020","article-title":"The Molecular Basis of Heterochromatin Assembly and Epigenetic Inheritance","volume":"83","author":"Grewal","year":"2023","journal-title":"Mol. Cell"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41401-025-01479-w","article-title":"Concurrent Inhibition of P300\/CBP and FLT3 Enhances Cytotoxicity and Overcomes Resistance in Acute Myeloid Leukemia","volume":"46","author":"Chen","year":"2025","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/onc.2015.92","article-title":"The Epigenetic Regulators CBP and P300 Facilitate Leukemogenesis and Represent Therapeutic Targets in Acute Myeloid Leukemia","volume":"35","author":"Giotopoulos","year":"2016","journal-title":"Oncogene"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1476-4598-13-29","article-title":"Histone Acetyltransferase-Deficient P300 Mutants in Diffuse Large B Cell Lymphoma Have Altered Transcriptional Regulatory Activities and Are Required for Optimal Cell Growth","volume":"13","author":"Haery","year":"2014","journal-title":"Mol. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13148-023-01531-8","article-title":"Update on Histone Deacetylase Inhibitors in Peripheral T-Cell Lymphoma (PTCL)","volume":"15","author":"Lu","year":"2023","journal-title":"Clin. Epigenet."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1080\/10428194.2017.1298751","article-title":"A Phase 1 Trial of the HDAC Inhibitor AR-42 in Patients with Multiple Myeloma and T- and B-Cell Lymphomas","volume":"58","author":"Sborov","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1038\/s41467-024-47701-x","article-title":"EZH2 Mutations in Follicular Lymphoma Distort H3K27me3 Profiles and Alter Transcriptional Responses to PRC2 Inhibition","volume":"15","author":"Romero","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.gendis.2019.05.001","article-title":"Mutations in EZH2 Are Associated with Poor Prognosis for Patients with Myeloid Neoplasms","volume":"6","author":"Zhang","year":"2019","journal-title":"Genes Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ccell.2024.11.006","article-title":"EZH2 inhibition enhances t-cell immunotherapies by inducing lymphoma immunogenicity and improving t-cell function","volume":"43","author":"Isshiki","year":"2025","journal-title":"Cancer Cell"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/0008-5472.CAN-20-2147","article-title":"EZH2-Targeted Therapies in Cancer: Hype or a Reality","volume":"80","author":"Eich","year":"2020","journal-title":"Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1517\/13543784.2016.1164140","article-title":"An Overview of Investigational Histone Deacetylase Inhibitors (HDACis) for the Treatment of Non-Hodgkin\u2019s Lymphoma","volume":"25","author":"Apuri","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/s41375-018-0062-8","article-title":"Histone Deacetylase (HDAC) Inhibitor ACY241 Enhances Anti-Tumor Activities of Antigen-Specific Central Memory Cytotoxic T Lymphocytes against Multiple Myeloma and Solid Tumors","volume":"32","author":"Bae","year":"2018","journal-title":"Leukemia"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1158\/1078-0432.CCR-14-3119","article-title":"FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma","volume":"21","author":"Lee","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/sj.jid.5700001","article-title":"Cytotoxic T Cells","volume":"126","author":"Andersen","year":"2006","journal-title":"J. Investig. Dermatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"392","DOI":"10.4049\/jimmunol.1701413","article-title":"Hitting the Target: How T Cells Detect and Eliminate Tumors","volume":"200","author":"Zamora","year":"2018","journal-title":"J. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jaci.2018.07.014","article-title":"Epigenetic Mechanisms Regulating T-Cell Responses","volume":"142","author":"Schmidl","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Dolina, J.S., Van Braeckel-Budimir, N., Thomas, G.D., and Salek-Ardakani, S. (2021). CD8+ T Cell Exhaustion in Cancer. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.715234"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/s41590-022-01224-z","article-title":"Epigenetic Regulation of T Cell Exhaustion","volume":"23","author":"Belk","year":"2022","journal-title":"Nat. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nri.2017.146","article-title":"Epigenetic Control of CD8+ T Cell Differentiation","volume":"18","author":"Henning","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","article-title":"Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms","volume":"52","author":"Beltra","year":"2020","journal-title":"Immunity"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX Transcriptionally and Epigenetically Programs CD8+ T Cell Exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41590-020-0760-z","article-title":"Early Precursor T Cells Establish and Propagate T Cell Exhaustion in Chronic Infection","volume":"21","author":"Utzschneider","year":"2020","journal-title":"Nat. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Buteyn, N.J., LaMantia, S.J., Burke, C.G., Sartori, V.J., Deering-Gardner, E., DeBruine, Z.J., Kamarudin, D., Chandler, D.P., Monovich, A.C., and Perez, M.W. (2025). EZH2-Driven Immune Evasion at Disease Presentation Defines a Targetable High-Risk Subset of Acute Leukemia Exemplified by t(16;21) FUS::ERG AML. bioRxiv, 2024.05.14.594150.","DOI":"10.1101\/2024.05.14.594150"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"E1116","DOI":"10.1073\/pnas.1501199112","article-title":"Mutations in Early Follicular Lymphoma Progenitors Are Associated with Suppressed Antigen Presentation","volume":"112","author":"Green","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/sj.bjc.6601602","article-title":"Inactivation of Class II Transactivator by DNA Methylation and Histone Deacetylation Associated with Absence of HLA-DR Induction by Interferon-\u03b3 in Haematopoietic Tumour Cells","volume":"90","author":"Morimoto","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e179703","DOI":"10.1172\/JCI179703","article-title":"An Epigenetic Pathway Regulates MHC-II Expression and Function in B Cell Lymphoma Models","volume":"135","author":"Zhang","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/s41375-023-01817-z","article-title":"Chronic Lymphocytic Leukemia Presence Impairs Antigen-Specific CD8+ T-Cell Responses through Epigenetic Reprogramming towards Short-Lived Effectors","volume":"37","author":"Martens","year":"2023","journal-title":"Leukemia"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1038\/s41375-019-0441-9","article-title":"CD8+ T Cells Expand Stem and Progenitor Cells in Favorable but Not Adverse Risk Acute Myeloid Leukemia","volume":"33","author":"Radpour","year":"2019","journal-title":"Leukemia"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Radpour, R., Stucki, M., Riether, C., and Ochsenbein, A.F. (2021). Epigenetic Silencing of Immune-Checkpoint Receptors in Bone Marrow- Infiltrating T Cells in Acute Myeloid Leukemia. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.663406"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41467-023-36193-w","article-title":"Myelodysplastic Syndrome Associated TET2 Mutations Affect NK Cell Function and Genome Methylation","volume":"14","author":"Boy","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"111299","DOI":"10.1016\/j.biopha.2021.111299","article-title":"Targeting the NKG2D\/NKG2D-L Axis in Acute Myeloid Leukemia","volume":"137","author":"Wu","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Xiao, Y., Chen, J., Wang, J., Guan, W., Wang, M., Zhang, L., Wang, Z., Wang, L., and Yu, L. (2021). Acute Myeloid Leukemia Epigenetic Immune Escape from Nature Killer Cells by ICAM-1. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.751834"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"eadp0004","DOI":"10.1126\/scitranslmed.adp0004","article-title":"BATF Is a Major Driver of NK Cell Epigenetic Reprogramming and Dysfunction in AML","volume":"16","author":"Kumar","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Que, Y., Li, H., Lin, L., Zhu, X., Xiao, M., Wang, Y., Zhu, L., and Li, D. (2021). Study on the Immune Escape Mechanism of Acute Myeloid Leukemia with DNMT3A Mutation. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.653030"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41392-020-00437-8","article-title":"CREBBP\/EP300 Mutations Promoted Tumor Progression in Diffuse Large B-Cell Lymphoma through Altering Tumor-Associated Macrophage Polarization via FBXW7-NOTCH-CCL2\/CSF1 Axis","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41419-021-03748-y","article-title":"BMI1 Regulates Multiple Myeloma-Associated Macrophage\u2019s pro-Myeloma Functions","volume":"12","author":"Zhang","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.isci.2018.12.016","article-title":"MOZ Forms an Autoregulatory Feedback Loop with miR-223 in AML and Monocyte\/Macrophage Development","volume":"11","author":"Jiang","year":"2018","journal-title":"iScience"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"9571","DOI":"10.1073\/pnas.0503726102","article-title":"Central Memory Self\/Tumor-Reactive CD8+ T Cells Confer Superior Antitumor Immunity Compared with Effector Memory T Cells","volume":"102","author":"Klebanoff","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"110079","DOI":"10.1016\/j.celrep.2021.110079","article-title":"CD19-CAR T Cells Undergo Exhaustion DNA Methylation Programming in Patients with Acute Lymphoblastic Leukemia","volume":"37","author":"Zebley","year":"2021","journal-title":"Cell Rep."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","article-title":"Immune Checkpoint Therapy for Solid Tumours: Clinical Dilemmas and Future Trends","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.annonc.2020.03.287","article-title":"Outcomes with Durvalumab by Tumour PD-L1 Expression in Unresectable, Stage III Non-Small-Cell Lung Cancer in the PACIFIC Trial","volume":"31","author":"Spira","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/471561a","article-title":"Melanoma Drug Wins US Approval","volume":"471","author":"Ledford","year":"2011","journal-title":"Nature"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune Checkpoint Signaling and Cancer Immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41408-021-00453-z","article-title":"Nivolumab Maintenance in High-Risk Acute Myeloid Leukemia Patients: A Single-Arm, Open-Label, Phase II Study","volume":"11","author":"Reville","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/2643-3230.BCD-21-0070","article-title":"Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed\/Refractory Acute Myeloid Leukemia","volume":"2","author":"Zeidner","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"101247","DOI":"10.1016\/j.beha.2021.101247","article-title":"Immune Checkpoint Inhibitors in Acute Myeloid Leukemia","volume":"34","author":"Daver","year":"2021","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Agrawal, V., and Salhotra, A. (2026). Overcoming Resistance to Immune Checkpoint Inhibitor Therapy in Acute Myeloid Leukemia. Front Oncol., 16.","DOI":"10.3389\/fonc.2026.1608433"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"40558","DOI":"10.18632\/oncotarget.9941","article-title":"Phenotypic Alteration of CD8 + T Cells in Chronic Lymphocytic Leukemia Is Associated with Epigenetic Reprogramming","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"9612","DOI":"10.18632\/oncotarget.3324","article-title":"Hypomethylation and Up-Regulation of PD-1 in T Cells by Azacytidine in MDS\/AML Patients: A Rationale for Combined Targeting of PD-1 and DNA Methylation","volume":"6","author":"Treppendahl","year":"2015","journal-title":"Oncotarget"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/leu.2016.328","article-title":"PD-L1 (CD274) Promoter Methylation Predicts Survival in Patients with Acute Myeloid Leukemia","volume":"31","author":"Goltz","year":"2017","journal-title":"Leukemia"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune Signature Drives Leukemia Escape and Relapse after Hematopoietic Cell Transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/bloodadvances.2019000445","article-title":"Recurrent Genetic HLA Loss in AML Relapsed after Matched Unrelated Allogeneic Hematopoietic Cell Transplantation","volume":"3","author":"Jan","year":"2019","journal-title":"Blood Adv."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1038\/s41467-023-38113-4","article-title":"Leukemia Relapse via Genetic Immune Escape after Allogeneic Hematopoietic Cell Transplantation","volume":"14","author":"Pagliuca","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune Escape of Relapsed AML Cells after Allogeneic Transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2073050","DOI":"10.1080\/2162402X.2022.2073050","article-title":"NPM1 and DNMT3A Mutations Are Associated with Distinct Blast Immunophenotype in Acute Myeloid Leukemia","volume":"11","author":"Schetelig","year":"2022","journal-title":"Oncoimmunology"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1158\/2159-8290.CD-21-0980","article-title":"Integrated Multiomic Profiling Identifies the Epigenetic Regulator PRC2 as a Therapeutic Target to Counteract Leukemia Immune Escape and Relapse","volume":"12","author":"Gambacorta","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2019.03.011","article-title":"Molecular Mechanisms Directing PRC2 Recruitment and H3K27 Methylation","volume":"74","author":"Laugesen","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41422-021-00606-6","article-title":"Mechanisms of Polycomb Group Protein Function in Cancer","volume":"32","author":"Parreno","year":"2022","journal-title":"Cell Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","article-title":"Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition","volume":"9","author":"Ennishi","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1158\/2159-8290.CD-16-0975","article-title":"CREBBP Inactivation Promotes the Development of HDAC3 Dependent Lymphomas","volume":"7","author":"Jiang","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.celrep.2015.10.008","article-title":"Genomic Alterations in CIITA Are Frequent in Primary Mediastinal Large B Cell Lymphoma and Are Associated with Diminished MHC Class II Expression","volume":"13","author":"Mottok","year":"2015","journal-title":"Cell Rep."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.it.2006.07.007","article-title":"Epigenetic Regulation of MHC-II and CIITA Genes","volume":"27","author":"Wright","year":"2006","journal-title":"Trends Immunol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1548243","DOI":"10.1080\/2162402X.2018.1548243","article-title":"CIITA-Related Block of HLA Class II Expression, Upregulation of HLA Class I, and Heterogeneous Expression of Immune Checkpoints in Hepatocarcinomas: Implications for New Therapeutic Approaches","volume":"8","author":"Ramia","year":"2019","journal-title":"OncoImmunology"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC Class II Transactivator CIITA Is a Recurrent Gene Fusion Partner in Lymphoid Cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"E437","DOI":"10.1002\/ijc.26478","article-title":"CIITA Is Silenced by Epigenetic Mechanisms That Prevent the Recruitment of Transactivating Factors in Rhabdomyosarcoma Cells","volume":"131","author":"Londhe","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1167\/iovs.04-0111","article-title":"Epigenetic Silencing of the CIITA Gene and Posttranscriptional Regulation of Class II MHC Genes in Ocular Melanoma Cells","volume":"45","author":"Radosevich","year":"2004","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1182\/blood.2024024518","article-title":"KDM6A Regulates Immune Response Genes in Multiple Myeloma","volume":"144","author":"Riva","year":"2024","journal-title":"Blood"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Paul, S., and Lal, G. (2017). The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01124"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/JLB.MR0718-269R","article-title":"Mechanisms of Natural Killer Cell-Mediated Cellular Cytotoxicity","volume":"105","author":"Prager","year":"2019","journal-title":"J. Leukoc. Biol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1182\/blood-2009-08-238469","article-title":"Regulation of Human NK-Cell Cytokine and Chemokine Production by Target Cell Recognition","volume":"115","author":"Fauriat","year":"2010","journal-title":"Blood"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1038\/s41467-022-31764-9","article-title":"Hypoxia Induces HIF1\u03b1-Dependent Epigenetic Vulnerability in Triple Negative Breast Cancer to Confer Immune Effector Dysfunction and Resistance to Anti-PD-1 Immunotherapy","volume":"13","author":"Ma","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Xia, M., Wang, B., Wang, Z., Zhang, X., and Wang, X. (2021). Epigenetic Regulation of NK Cell-Mediated Antitumor Immunity. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.672328"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1172\/JCI125916","article-title":"Chronic Stimulation Drives Human NK Cell Dysfunction and Epigenetic Reprograming","volume":"129","author":"Merino","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in Myeloid Cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.2834","article-title":"The Transcription Factor BATF Operates as an Essential Differentiation Checkpoint in Early Effector CD8+ T Cells","volume":"15","author":"Kurachi","year":"2014","journal-title":"Nat. Immunol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.celrep.2019.09.064","article-title":"Batf Pioneers the Reorganization of Chromatin in Developing Effector T Cells via Ets1-Dependent Recruitment of Ctcf","volume":"29","author":"Pham","year":"2019","journal-title":"Cell Rep."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1158\/1541-7786.MCR-10-0375","article-title":"Batf Promotes Growth Arrest and Terminal Differentiation of Mouse Myeloid Leukemia Cells","volume":"9","author":"Liao","year":"2011","journal-title":"Mol. Cancer Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/mc.23715","article-title":"BATF Promotes Extramedullary Infiltration through TGF-\u03921\/Smad\/MMPs Axis in Acute Myeloid Leukemia","volume":"63","author":"Zhang","year":"2024","journal-title":"Mol. Carcinog."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.ccell.2022.09.013","article-title":"Depletion of BATF in CAR-T Cells Enhances Antitumor Activity by Inducing Resistance against Exhaustion and Formation of Central Memory Cells","volume":"40","author":"Zhang","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41590-021-00964-8","article-title":"BATF and IRF4 Cooperate to Counter Exhaustion in Tumor-Infiltrating CAR T Cells","volume":"22","author":"Seo","year":"2021","journal-title":"Nat. Immunol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41392-020-00348-8","article-title":"Immune Checkpoint Molecules in Natural Killer Cells as Potential Targets for Cancer Immunotherapy","volume":"5","author":"Cao","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.clim.2016.01.008","article-title":"Roles of CD48 in Regulating Immunity and Tolerance","volume":"164","author":"McArdel","year":"2016","journal-title":"Clin. Immunol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood-2013-09-526590","article-title":"Immune Evasion by Oncogenic Proteins of Acute Myeloid Leukemia","volume":"123","author":"Elias","year":"2014","journal-title":"Blood"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1080\/10428194.2020.1849680","article-title":"AML1-ETO Inhibits Acute Myeloid Leukemia Immune Escape by CD48","volume":"62","author":"Wang","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/gene.2014.58","article-title":"Methylation of NKG2D Ligands Contributes to Immune System Evasion in Acute Myeloid Leukemia","volume":"16","author":"Fernandez","year":"2015","journal-title":"Genes Immun."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13045-016-0362-2","article-title":"Inhibition of Bromodomain and Extra-Terminal (BET) Proteins Increases NKG2D Ligand MICA Expression and Sensitivity to NK Cell-Mediated Cytotoxicity in Multiple Myeloma Cells: Role of cMYC-IRF4-miR-125b Interplay","volume":"9","author":"Abruzzese","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Basak, U., Sarkar, T., Mukherjee, S., Chakraborty, S., Dutta, A., Dutta, S., Nayak, D., Kaushik, S., Das, T., and Sa, G. (2023). Tumor-Associated Macrophages: An Effective Player of the Tumor Microenvironment. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1295257"},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Pan, Y., Yu, Y., Wang, X., and Zhang, T. (2020). Tumor-Associated Macrophages in Tumor Immunity. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.583084"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Tan, Y., Wang, M., Zhang, Y., Ge, S., Zhong, F., Xia, G., and Sun, C. (2021). Tumor-Associated Macrophages: A Potential Target for Cancer Therapy. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.693517"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s44313-025-00119-w","article-title":"Macrophage Polarization in Hematologic Cancers: Mechanisms and Therapeutic Strategies","volume":"61","author":"Chen","year":"2026","journal-title":"Blood Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1101\/gad.1393106","article-title":"MOZ Is Essential for Maintenance of Hematopoietic Stem Cells","volume":"20","author":"Katsumoto","year":"2006","journal-title":"Genes Dev."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/jcp.24617","article-title":"The MOZ Histone Acetyltransferase in Epigenetic Signaling and Disease","volume":"229","author":"Carlson","year":"2014","journal-title":"J. Cell. Physiol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1535-6108(03)00051-5","article-title":"MOZ-TIF2-Induced Acute Myeloid Leukemia Requires the MOZ Nucleosome Binding Motif and TIF2-Mediated Recruitment of CBP","volume":"3","author":"Deguchi","year":"2003","journal-title":"Cancer Cell"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"7852742","DOI":"10.1155\/2018\/7852742","article-title":"The Kat in the HAT: The Histone Acetyl Transferase Kat6b (MYST4) Is Downregulated in Murine Macrophages in Response to LPS","volume":"2018","author":"Shukla","year":"2018","journal-title":"Mediat. Inflamm."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Wang, X., Chen, J., Lai, Y., Wang, Y., Hu, K., Wu, M., Yang, N., and Huang, Y. (2026). Lysine Acetyltransferase 6A Drives M1 Macrophage Polarization Through Metabolic Reprogramming in Sepsis-Induced Acute Lung Injury. Biomolecules, 16.","DOI":"10.3390\/biom16040609"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"102033","DOI":"10.1016\/j.mcp.2025.102033","article-title":"DNMT3A Triggers Tumorigenesis of Non-Small Cell Lung Cancer through Regulation of SLIT2 Methylation and SLIT2-Mediated Macrophage M1\/M2 Polarization","volume":"82","author":"Ni","year":"2025","journal-title":"Mol. Cell. Probes"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.immuni.2022.06.022","article-title":"DNA Methyltransferase 3 Alpha and TET Methylcytosine Dioxygenase 2 Restrain Mitochondrial DNA-Mediated Interferon Signaling in Macrophages","volume":"55","author":"Cobo","year":"2022","journal-title":"Immunity"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.freeradbiomed.2022.03.031","article-title":"Epigenetic Activation of RBM15 Promotes Clear Cell Renal Cell Carcinoma Growth, Metastasis and Macrophage Infiltration by Regulating the m6A Modification of CXCL11","volume":"184","author":"Zeng","year":"2022","journal-title":"Free. Radic. Biol. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"8344","DOI":"10.7150\/thno.30707","article-title":"P300\/CBP Inhibitor A-485 Alleviates Acute Liver Injury by Regulating Macrophage Activation and Polarization","volume":"9","author":"Peng","year":"2019","journal-title":"Theranostics"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1158\/2326-6066.CIR-20-0555","article-title":"The IKZF1\u2013IRF4\/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages","volume":"9","author":"Mougiakakos","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/cac2.12228","article-title":"RGS12 Inhibits the Progression and Metastasis of Multiple Myeloma by Driving M1 Macrophage Polarization and Activation in the Bone Marrow Microenvironment","volume":"42","author":"Yuan","year":"2022","journal-title":"Cancer Commun."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Malfitano, A.M., Pisanti, S., Napolitano, F., Di Somma, S., Martinelli, R., and Portella, G. (2020). Tumor-Associated Macrophage Status in Cancer Treatment. Cancers, 12.","DOI":"10.3390\/cancers12071987"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.7150\/jca.30102","article-title":"High Numbers of CD163+ Tumor-Associated Macrophages Correlate with Poor Prognosis in Multiple Myeloma Patients Receiving Bortezomib-Based Regimens","volume":"10","author":"Wang","year":"2019","journal-title":"J. Cancer"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00277-012-1652-6","article-title":"Tumor-Associated Macrophages as a Prognostic Parameter in Multiple Myeloma","volume":"92","author":"Sucak","year":"2013","journal-title":"Ann. Hematol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/stem.1035","article-title":"Role of BMI1, a Stem Cell Factor, in Cancer Recurrence and Chemoresistance: Preclinical and Clinical Evidences","volume":"30","author":"Siddique","year":"2012","journal-title":"Stem Cells"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"e003975","DOI":"10.1136\/jitc-2021-003975","article-title":"Tumor-Associated Macrophages in Multiple Myeloma: Advances in Biology and Therapy","volume":"10","author":"Sun","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"28599","DOI":"10.1074\/jbc.M111.256297","article-title":"Monoubiquitination of H2AX Protein Regulates DNA Damage Response Signaling","volume":"286","author":"Pan","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.stem.2020.06.022","article-title":"BMI1 Inhibition Eliminates Residual Cancer Stem Cells after PD1 Blockade and Activates Antitumor Immunity to Prevent Metastasis and Relapse","volume":"27","author":"Jia","year":"2020","journal-title":"Cell Stem Cell"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1186\/s12967-026-07799-7","article-title":"m6A Methylation-Modified ETV1 Drives Multiple Myeloma Progression and M2 Polarization of Tumor-Associated Macrophage through Transcriptional Activation of RBMS1","volume":"24","author":"Liu","year":"2026","journal-title":"J. Transl. Med."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/s41375-024-02250-6","article-title":"Autophagy Degrades Immunogenic Endogenous Retroelements Induced by 5-Azacytidine in Acute Myeloid Leukemia","volume":"38","author":"Noronha","year":"2024","journal-title":"Leukemia"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/ajh.22141","article-title":"Cancer-Testis Antigen Expression and Its Epigenetic Modulation in Acute Myeloid Leukemia","volume":"86","author":"Atanackovic","year":"2011","journal-title":"Am. J. Hematol."},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Ebelt, N.D., Zuniga, E., Johnson, B.L., Diamond, D.J., and Manuel, E.R. (2020). 5-Azacytidine Potentiates Anti-Tumor Immunity in a Model of Pancreatic Ductal Adenocarcinoma. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00538"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"44159","DOI":"10.18632\/oncotarget.17395","article-title":"Epigenetic Modifiers Upregulate MHC II and Impede Ovarian Cancer Tumor Growth","volume":"8","author":"Turner","year":"2017","journal-title":"Oncotarget"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in Myelodysplastic Syndromes Is Enhanced by Treatment with Hypomethylating Agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4049\/jimmunol.182.1.259","article-title":"Epigenetic Regulation of Foxp3 Expression in Regulatory T Cells by DNA Methylation","volume":"182","author":"Lal","year":"2009","journal-title":"J. Immunol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1038\/bcj.2014.14","article-title":"5-Azacytidine Treatment Sensitizes Tumor Cells to T-Cell Mediated Cytotoxicity and Modulates NK Cells in Patients with Myeloid Malignancies","volume":"4","author":"Gang","year":"2014","journal-title":"Blood Cancer J."},{"key":"ref_184","first-page":"454","article-title":"Decitabine Treatment Sensitizes Tumor Cells to T-Cell-Mediated Cytotoxicity in Patients with Myelodysplastic Syndromes","volume":"9","author":"Zhang","year":"2017","journal-title":"Am. J. Transl. Res."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"12840","DOI":"10.18632\/oncotarget.7326","article-title":"Induction of Cancer Testis Antigen Expression in Circulating Acute Myeloid Leukemia Blasts Following Hypomethylating Agent Monotherapy","volume":"7","author":"Srivastava","year":"2016","journal-title":"Oncotarget"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1182\/blood-2002-11-3458","article-title":"5-Aza-2\u2032-Deoxycytidine (Decitabine) Treatment of Hematopoietic Malignancies: A Multimechanism Therapeutic Approach?","volume":"101","author":"Sigalotti","year":"2003","journal-title":"Blood"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"E10981","DOI":"10.1073\/pnas.1712514114","article-title":"Epigenetic Therapy Activates Type I Interferon Signaling in Murine Ovarian Cancer to Reduce Immunosuppression and Tumor Burden","volume":"114","author":"Stone","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1158\/2767-9764.CRC-24-0310","article-title":"Single-Cell Analysis of Bone Marrow CD8+ T Cells in Myeloid Neoplasms Reveals Pathways Associated with Disease Progression and Response to Treatment with Azacitidine","volume":"4","author":"Tasis","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/blood.2020009081","article-title":"Venetoclax Enhances T Cell\u2013Mediated Antileukemic Activity by Increasing ROS Production","volume":"138","author":"Lee","year":"2021","journal-title":"Blood"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/bjh.18783","article-title":"Oral Azacitidine Modulates the Bone Marrow Microenvironment in Patients with Acute Myeloid Leukaemia in Remission: A Subanalysis from the QUAZAR AML-001 Trial","volume":"201","author":"Menezes","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-022-00615-7","article-title":"Azacitidine-Induced Reconstitution of the Bone Marrow T Cell Repertoire Is Associated with Superior Survival in AML Patients","volume":"12","author":"Grimm","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_192","first-page":"2194","article-title":"Multicenter Phase 2 Study of Oral Azacitidine (CC-486) plus CHOP as Initial Treatment for PTCL","volume":"141","author":"Ruan","year":"2023","journal-title":"Blood"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.cell.2017.06.007","article-title":"De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation","volume":"170","author":"Ghoneim","year":"2017","journal-title":"Cell"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"eabh0272","DOI":"10.1126\/scitranslmed.abh0272","article-title":"Deleting DNMT3A in CAR T Cells Prevents Exhaustion and Enhances Antitumor Activity","volume":"13","author":"Prinzing","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"34178","DOI":"10.18632\/oncotarget.6213","article-title":"Imprint of 5-Azacytidine on the Natural Killer Cell Repertoire during Systemic Treatment for High-Risk Myelodysplastic Syndrome","volume":"6","author":"Sohlberg","year":"2015","journal-title":"Oncotarget"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"452.e1","DOI":"10.1016\/j.jtct.2025.11.039","article-title":"Decitabine Conditioning Improves Natural Killer Cell Maturation and Limits CD8+ T Cell Terminal Differentiation Post-Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients","volume":"32","author":"Grotens","year":"2026","journal-title":"Transplant. Cell. Ther."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1182\/blood-2017-06-790204","article-title":"Decitabine Enhances Targeting of AML Cells by CD34+ Progenitor-Derived NK Cells in NOD\/SCID\/IL2Rgnull Mice","volume":"131","author":"Cany","year":"2018","journal-title":"Blood"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s41375-018-0070-8","article-title":"Hypomethylating Agents in Combination with Immune Checkpoint Inhibitors in Acute Myeloid Leukemia and Myelodysplastic Syndromes","volume":"32","author":"Daver","year":"2018","journal-title":"Leukemia"},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Ebelt, N.D., and Manuel, E.R. (2022). 5-Azacytidine-Mediated Modulation of the Immune Microenvironment in Murine Acute Myeloid Leukemia. Cancers, 15.","DOI":"10.3390\/cancers15010118"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1182\/blood-2024-210370","article-title":"Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)","volume":"144","author":"Stempel","year":"2024","journal-title":"Blood"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"11414","DOI":"10.18632\/oncotarget.23356","article-title":"Role of Novel Histone Modifications in Cancer","volume":"9","author":"Shanmugam","year":"2017","journal-title":"Oncotarget"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-018-0119-y","article-title":"The Biological Significance of Histone Modifiers in Multiple Myeloma: Clinical Applications","volume":"8","author":"Ohguchi","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"San Jos\u00e9-En\u00e9riz, E., Gimenez-Camino, N., Agirre, X., and Prosper, F. (2019). HDAC Inhibitors in Acute Myeloid Leukemia. Cancers, 11.","DOI":"10.3390\/cancers11111794"},{"key":"ref_204","first-page":"277","article-title":"The Roles of Histone Modifications in Tumorigenesis and Associated Inhibitors in Cancer Therapy","volume":"2","author":"Yang","year":"2022","journal-title":"J. Natl. Cancer Cent."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4155\/fmc.12.3","article-title":"Targeted Cancer Therapy: Giving Histone Deacetylase Inhibitors All They Need to Succeed","volume":"4","author":"Gryder","year":"2012","journal-title":"Future Med. Chem."},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"Borcoman, E., Kamal, M., Marret, G., Dupain, C., Castel-Ajgal, Z., and Le Tourneau, C. (2022). HDAC Inhibition to Prime Immune Checkpoint Inhibitors. Cancers, 14.","DOI":"10.3390\/cancers14010066"},{"key":"ref_207","doi-asserted-by":"crossref","unstructured":"Ma, X., Zhao, M., Wu, Z.-X., Yao, J., Zhang, L., Wang, J., Hu, Z., Wei, L., and Chen, Z.-S. (2022). The Histone Deacetylase Inhibitor I13 Induces Differentiation of M2, M3 and M5 Subtypes of Acute Myeloid Leukemia Cells and Leukemic Stem-Like Cells. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.855570"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/(SICI)1098-2264(199711)20:3<215::AID-GCC1>3.0.CO;2-5","article-title":"Dendritic Cells Generated from Blood Precursors of Chronic Myelogenous Leukemia Patients Carry the Philadelphia Translocation and Can Induce a CML-Specific Primary Cytotoxic T-Cell Response","volume":"20","author":"Eibl","year":"1997","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1002\/(SICI)1521-4141(199908)29:08<2567::AID-IMMU2567>3.0.CO;2-S","article-title":"Human Acute Myeloblastic Leukemia Cells Differentiate in Vitro into Mature Dendritic Cells and Induce the Differentiation of Cytotoxic T Cells against Autologous Leukemias","volume":"29","author":"Charbonnier","year":"1999","journal-title":"Eur. J. Immunol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood.V98.13.3750","article-title":"Circulating Blood Dendritic Cells from Myeloid Leukemia Patients Display Quantitative and Cytogenetic Abnormalities as Well as Functional Impairment","volume":"98","author":"Mohty","year":"2001","journal-title":"Blood"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1189\/jlb.1103581","article-title":"Histone Deacetylase Inhibition Improves Dendritic Cell Differentiation of Leukemic Blasts with AML1-Containing Fusion Proteins","volume":"76","author":"Moldenhauer","year":"2004","journal-title":"J. Leukoc. Biol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1158\/2159-8290.CD-20-1145","article-title":"Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML","volume":"12","author":"Salmon","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Maharaj, K., Powers, J.J., Mediavilla-Varela, M., Achille, A., Gamal, W., Quayle, S., Jones, S.S., Sahakian, E., and Pinilla-Ibarz, J. (2020). HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the E\u03bc-TCL1 Model. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.590072"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"e1492","DOI":"10.1002\/cti2.1492","article-title":"Effective \u0393\u03b4 T-cell Clinical Therapies: Current Limitations and Future Perspectives for Cancer Immunotherapy","volume":"13","author":"Revesz","year":"2024","journal-title":"Clin. Transl. Immunol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"e27572","DOI":"10.4161\/onci.27572","article-title":"\u0393\u03b4 T Cells for Cancer Immunotherapy","volume":"3","author":"Fisher","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.omto.2020.08.003","article-title":"HDAC Inhibitor LBH589 Suppresses the Proliferation but Enhances the Antileukemic Effect of Human \u03b3\u03b4T Cells","volume":"18","author":"He","year":"2020","journal-title":"Mol. Ther.-Oncolytics"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1111\/cas.15122","article-title":"The EZH2 Inhibitor Tazemetostat Upregulates the Expression of CCL17\/TARC in B-Cell Lymphoma and Enhances T-Cell Recruitment","volume":"112","author":"Yuan","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1182\/blood-2013-02-482513","article-title":"Downregulation of the Activating NKp30 Ligand B7-H6 by HDAC Inhibitors Impairs Tumor Cell Recognition by NK Cells","volume":"122","author":"Fiegler","year":"2013","journal-title":"Blood"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s11095-013-1231-0","article-title":"The Narrow-Spectrum HDAC Inhibitor Entinostat Enhances NKG2D Expression Without NK Cell Toxicity, Leading to Enhanced Recognition of Cancer Cells","volume":"32","author":"Zhu","year":"2015","journal-title":"Pharm. Res."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00262-016-1900-z","article-title":"Histone Deacetylase Inhibitors Enhance CD1d-Dependent NKT Cell Responses to Lymphoma","volume":"65","author":"Tiper","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1593\/neo.121236","article-title":"Valproic Acid Upregulates NKG2D Ligand Expression through an ERK-Dependent Mechanism and Potentially Enhances NK Cell-Mediated Lysis of Myeloma","volume":"14","author":"Wu","year":"2012","journal-title":"Neoplasia"},{"key":"ref_222","doi-asserted-by":"crossref","unstructured":"Eckschlager, T., Plch, J., Stiborova, M., and Hrabeta, J. (2017). Histone Deacetylase Inhibitors as Anticancer Drugs. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18071414"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/17501911.2026.2637418","article-title":"DNA Methyltransferase Inhibitors in Oncology: Clinical Progress, Limitations and Future Directions","volume":"18","author":"Michael","year":"2026","journal-title":"Epigenomics"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3109\/14653249.2010.529893","article-title":"Epigenetic Modulation of MAGE-A3 Antigen Expression in Multiple Myeloma Following Treatment with the Demethylation Agent 5-Azacitidine and the Histone Deacetlyase Inhibitor MGCD0103","volume":"13","author":"Szmania","year":"2011","journal-title":"Cytotherapy"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood-2009-11-249474","article-title":"Induction of a CD8+ T-Cell Response to the MAGE Cancer Testis Antigen by Combined Treatment with Azacitidine and Sodium Valproate in Patients with Acute Myeloid Leukemia and Myelodysplasia","volume":"116","author":"Goodyear","year":"2010","journal-title":"Blood"},{"key":"ref_226","doi-asserted-by":"crossref","unstructured":"Yao, Y., Zhou, J., Wang, L., Gao, X., Ning, Q., Jiang, M., Wang, J., Wang, L., and Yu, L. (2013). Increased PRAME-Specific CTL Killing of Acute Myeloid Leukemia Cells by Either a Novel Histone Deacetylase Inhibitor Chidamide Alone or Combined Treatment with Decitabine. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0070522"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1158\/1078-0432.CCR-13-1576","article-title":"Reducing TNF Receptor 2+ Regulatory T Cells via the Combined Action of Azacitidine and the HDAC Inhibitor, Panobinostat for Clinical Benefit in Acute Myeloid Leukemia Patients","volume":"20","author":"Govindaraj","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrc3670","article-title":"Tumour Antigens Recognized by T Lymphocytes: At the Core of Cancer Immunotherapy","volume":"14","author":"Coulie","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","article-title":"Antigen Presentation in Cancer: Insights into Tumour Immunogenicity and Immune Evasion","volume":"21","author":"Jhunjhunwala","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.molonc.2011.02.001","article-title":"The Biology of Cancer Testis Antigens: Putative Function, Regulation and Therapeutic Potential","volume":"5","author":"Fratta","year":"2011","journal-title":"Mol. Oncol."},{"key":"ref_231","first-page":"257695","article-title":"Cancer\/Testis Antigen MAGE-C1\/CT7: New Target for Multiple Myeloma Therapy","volume":"2012","author":"Vettore","year":"2012","journal-title":"J. Immunol. Res."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/leu.2012.145","article-title":"Leukemia-Associated Antigens and Their Relevance to the Immunotherapy of Acute Myeloid Leukemia","volume":"26","author":"Anguille","year":"2012","journal-title":"Leukemia"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-11-3687","article-title":"T Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis","volume":"72","author":"Facciabene","year":"2012","journal-title":"Cancer Res."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"e1484981","DOI":"10.1080\/2162402X.2018.1484981","article-title":"Epigenetic Treatment of Multiple Myeloma Mediates Tumor Intrinsic and Extrinsic Immunomodulatory Effects","volume":"7","author":"Melhaoui","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.3324\/haematol.2024.286559","article-title":"A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome","volume":"110","author":"Bouligny","year":"2025","journal-title":"Haematologica"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1182\/bloodadvances.2021006138","article-title":"A Randomized Phase 2 Trial of Azacitidine with or without Durvalumab as First-Line Therapy for Older Patients with AML","volume":"6","author":"Zeidan","year":"2022","journal-title":"Blood Adv."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"E32","DOI":"10.1002\/ajh.27161","article-title":"Phase Ib Study of Sabatolimab (MBG453), a Novel Immunotherapy Targeting TIM-3 Antibody, in Combination with Decitabine or Azacitidine in High- or Very High-Risk Myelodysplastic Syndromes","volume":"99","author":"Brunner","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2217\/fon-2022-1237","article-title":"STIMULUS-MDS2 Design and Rationale: A Phase III Trial with the Anti-TIM-3 Sabatolimab (MBG453) + Azacitidine in Higher Risk MDS and CMML-2","volume":"19","author":"Zeidan","year":"2023","journal-title":"Future Oncol."},{"key":"ref_239","doi-asserted-by":"crossref","unstructured":"Giudice, V., Serio, B., Ferrara, I., Manzo, P., Gorrese, M., Pepe, R., Bertolini, A., D\u2019Alto, F., Verdesca, F., and Langella, M. (2022). Clinical Efficacy of Azacytidine and Venetoclax and Prognostic Impact of Tim-3 and Galectin-9 in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes: A Single-Center Real-Life Experience. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1052060"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41698-025-00933-6","article-title":"Unlocking the Potential of TIGIT in Enhancing Therapeutic Strategies for Acute Myeloid Leukemia through Combined Azacitidine Therapy","volume":"9","author":"Zhang","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"e70725","DOI":"10.1002\/cam4.70725","article-title":"A Phase I\/IB, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab in Combination with Vorinostat in Patients with Advanced Prostate, Renal or Urothelial Carcinoma","volume":"14","author":"Pili","year":"2025","journal-title":"Cancer Med."},{"key":"ref_242","doi-asserted-by":"crossref","unstructured":"Sun, Y., Hong, J.H., Ning, Z., Pan, D., Fu, X., Lu, X., and Tan, J. (2022). Therapeutic Potential of Tucidinostat, a Subtype-Selective HDAC Inhibitor, in Cancer Treatment. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.932914"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1158\/2326-6066.CIR-18-0875","article-title":"Histone Deacetylase Inhibition Sensitizes PD1 Blockade\u2013Resistant B-Cell Lymphomas","volume":"7","author":"Wang","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"104420","DOI":"10.1016\/j.ebiom.2022.104420","article-title":"Histone Deacetylases Inhibitor Chidamide Synergizes with Humanized PD1 Antibody to Enhance T-Cell Chemokine Expression and Augment Ifn-\u03b3 Response in NK-T Cell Lymphoma","volume":"87","author":"Wen","year":"2022","journal-title":"eBioMedicine"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41392-023-01647-6","article-title":"Bromodomain and Extraterminal (BET) Proteins: Biological Functions, Diseases and Targeted Therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1038\/s41467-019-10652-9","article-title":"Targeting Enhancer Switching Overcomes Non-Genetic Drug Resistance in Acute Myeloid Leukaemia","volume":"10","author":"Bell","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"16669","DOI":"10.1073\/pnas.1108190108","article-title":"Targeting MYC Dependence in Cancer by Inhibiting BET Bromodomains","volume":"108","author":"Mertz","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.gendis.2022.03.004","article-title":"BET in Hematologic Tumors: Immunity, Pathogenesis, Clinical Trials and Drug Combinations","volume":"10","author":"Ma","year":"2022","journal-title":"Genes Dis."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/s41416-021-01321-0","article-title":"Achieving Clinical Success with BET Inhibitors as Anti-Cancer Agents","volume":"124","author":"Shorstova","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_250","doi-asserted-by":"crossref","unstructured":"Sun, Y., Han, J., Wang, Z., Li, X., Sun, Y., and Hu, Z. (2021). Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.621093"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"53997","DOI":"10.18632\/oncotarget.9804","article-title":"Targeting BET Bromodomain Proteins in Solid Tumors","volume":"7","author":"Sahai","year":"2016","journal-title":"Oncotarget"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.2147\/OTT.S100515","article-title":"BET Inhibitors in the Treatment of Hematologic Malignancies: Current Insights and Future Prospects","volume":"9","author":"Abedin","year":"2016","journal-title":"OncoTargets Ther."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1158\/2326-6066.CIR-21-0224","article-title":"BET Inhibition Enhances TNF-Mediated Antitumor Immunity","volume":"10","author":"Wellinger","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"5534","DOI":"10.1073\/pnas.1721559115","article-title":"Modeling Combination Therapy for Breast Cancer with BET and Immune Checkpoint Inhibitors","volume":"115","author":"Lai","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00432-021-03885-z","article-title":"Targeting CCR2+ Macrophages with BET Inhibitor Overcomes Adaptive Resistance to Anti-VEGF Therapy in Ovarian Cancer","volume":"148","author":"Wu","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.celrep.2017.02.011","article-title":"BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1","volume":"18","author":"Hogg","year":"2017","journal-title":"Cell Rep."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41375-023-01808-0","article-title":"BET Inhibitors Rescue Anti-PD1 Resistance by Enhancing TCF7 Accessibility in Leukemia-Derived Terminally Exhausted CD8+ T Cells","volume":"37","author":"Romine","year":"2023","journal-title":"Leukemia"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/bloodadvances.2021005487","article-title":"A Randomized Phase 2 Trial of Azacitidine with or without Durvalumab as First-Line Therapy for Higher-Risk Myelodysplastic Syndromes","volume":"6","author":"Zeidan","year":"2022","journal-title":"Blood Adv."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00277-023-05552-4","article-title":"A Multicenter Phase Ib Trial of the Histone Deacetylase Inhibitor Entinostat in Combination with Pembrolizumab in Patients with Myelodysplastic Syndromes\/Neoplasms or Acute Myeloid Leukemia Refractory to Hypomethylating Agents","volume":"103","author":"Bewersdorf","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/nm.4125","article-title":"Distinct Evolution and Dynamics of Epigenetic and Genetic Heterogeneity in Acute Myeloid Leukemia","volume":"22","author":"Li","year":"2016","journal-title":"Nat. Med."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional Genomic Landscape of Acute Myeloid Leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature"},{"key":"ref_262","doi-asserted-by":"crossref","unstructured":"Lamble, A.J., and Lind, E.F. (2018). Targeting the Immune Microenvironment in Acute Myeloid Leukemia: A Focus on T Cell Immunity. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00213"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/ajh.24780","article-title":"Outcome of Elderly Patients after Failure to Hypomethylating Agents given as Frontline Therapy for Acute Myeloid Leukemia: Single Institution Experience*","volume":"92","author":"Nanah","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccell.2026.07.011","article-title":"Latent Effector T Cells Mediate Immunotherapy Responses in the Bone Marrow Microenvironment","volume":"44","author":"Kehl","year":"2026","journal-title":"Cancer Cell"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41375-023-01838-8","article-title":"Inhibition of SUMOylation Enhances DNA Hypomethylating Drug Efficacy to Reduce Outgrowth of Hematopoietic Malignancies","volume":"37","author":"Kroonen","year":"2023","journal-title":"Leukemia"},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"e008654","DOI":"10.1136\/jitc-2023-008654","article-title":"Targeting Epigenetic Regulation and Post-Translational Modification with 5-Aza-2\u2032 Deoxycytidine and SUMO E1 Inhibition Augments T-Cell Receptor Therapy","volume":"12","author":"Kroonen","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1038\/s41467-021-26683-0","article-title":"Demethylating Therapy Increases Anti-CD123 CAR T Cell Cytotoxicity against Acute Myeloid Leukemia","volume":"12","author":"Hughes","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ccell.2022.04.001","article-title":"Non-Cleavable Hinge Enhances Avidity and Expansion of CAR-T Cells for Acute Myeloid Leukemia","volume":"40","author":"Leick","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.2147\/OTT.S198567","article-title":"Decitabine Enhances Cytotoxic Effect of T Cells with an Anti-CD19 Chimeric Antigen Receptor in Treatment of Lymphoma","volume":"12","author":"Li","year":"2019","journal-title":"OncoTargets Ther."},{"key":"ref_270","doi-asserted-by":"crossref","unstructured":"You, L., Han, Q., Zhu, L., Zhu, Y., Bao, C., Yang, C., Lei, W., and Qian, W. (2020). Decitabine-Mediated Epigenetic Reprograming Enhances Anti-Leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01787"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41467-020-20696-x","article-title":"Low-Dose Decitabine Priming Endows CAR T Cells with Enhanced and Persistent Antitumour Potential via Epigenetic Reprogramming","volume":"12","author":"Wang","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ccell.2025.01.013","article-title":"EZH1\/EZH2 Inhibition Enhances Adoptive T Cell Immunotherapy against Multiple Cancer Models","volume":"43","author":"Porazzi","year":"2025","journal-title":"Cancer Cell"},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"114065","DOI":"10.1016\/j.celrep.2024.114065","article-title":"Class I HDAC Inhibitors Enhance Antitumor Efficacy and Persistence of CAR-T Cells by Activation of the Wnt Pathway","volume":"43","author":"Zhu","year":"2024","journal-title":"Cell Rep."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"eadp9371","DOI":"10.1126\/sciadv.adp9371","article-title":"TET2 Regulates Early and Late Transitions in Exhausted CD8+ T Cell Differentiation and Limits CAR T Cell Function","volume":"10","author":"Dimitri","year":"2024","journal-title":"Sci. Adv."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4049\/jimmunol.1700559","article-title":"The Loss of TET2 Promotes CD8+ T Cell Memory Differentiation","volume":"200","author":"Carty","year":"2018","journal-title":"J. Immunol."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.immuni.2015.03.005","article-title":"The Methylcytosine Dioxygenase Tet2 Promotes DNA Demethylation and Activation of Cytokine Gene Expression in T Cells","volume":"42","author":"Ichiyama","year":"2015","journal-title":"Immunity"},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 Promotes the Therapeutic Efficacy of CD19-Targeted T Cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40164-025-00609-8","article-title":"TET2 Downregulation Enhances the Antitumor Efficacy of CD19 CAR T Cells in a Preclinical Model","volume":"14","author":"Kim","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"e145459","DOI":"10.1172\/JCI145459","article-title":"BET Bromodomain Protein Inhibition Reverses Chimeric Antigen Receptor Extinction and Reinvigorates Exhausted T Cells in Chronic Lymphocytic Leukemia","volume":"131","author":"Kong","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41586-022-05692-z","article-title":"TET2 Guards against Unchecked BATF3-Induced CAR T Cell Expansion","volume":"615","author":"Jain","year":"2023","journal-title":"Nature"},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/2159-8290.CD-22-1319","article-title":"Disruption of SUV39H1-Mediated H3K9 Methylation Sustains CAR T-Cell Function","volume":"14","author":"Jain","year":"2024","journal-title":"Cancer Discov."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/2985\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:12:13Z","timestamp":1789618333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/2985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":281,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18182985"],"URL":"https:\/\/doi.org\/10.3390\/cancers18182985","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]}}}